Spectroscopy- based development and validation of analytical technique for simultaneous estimation of bilastine montelukast

Abstract

Bilastine is a selective antagonist of the histamine H1 receptor. It binds to the H1 receptor and inhibits it from being activated, reducing allergy symptoms caused by the release of histamine from mast cells. As a result, it serves as antiallergenic, reducing allergy symptoms such nasal congestion and urticaria.Montelukast Sodium is a leukotriene receptor antagonist that binds to the CysLT type 1 receptor, assisting in the inhibition of any physiological activities of CysLTs such as LTC4, LTD4, and LTE4 at the receptor that may help asthma or allergic rhinitis. As a result, it's mostly used to treat and prevent asthma symptoms (such as wheezing and shortness of breath) as well as allergic rhinitis. Allergy rhinitis and mild to severe asthma are treated with a combination of both medicines. Analytical methods on Bilastine and Montelukast Sodium are discussed in this research. However, no ways for combining Bilastine with Montelukast Sodium are now available. Bilastine and Montelukast Sodium can be tested using UV, used to help design new analytical methods.

Stability Indicating Quality by Design-based Development and Validation of Bilastine and Montelukast by Ultra Performance Liquid Chromatography Method

“…5 The quality project from the planning stage to the end of the product life cycle is addressed by the QbD tool. 6 The literature suggests that a number of analytical techniques, including UV Spectroscopy, [7][8][9][10] high-performance liquid chromatography (HPLC), [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] high-performance thin layer chromatography (HPTLC), 17 and ultra performance liquid chromatography (UPLC ) 18,19 for the simultaneous determination of BIL and MON, have been reported. Except for spectrophotometry, none of these technologies were applied for analytical QbD in the published literature.…”